ATE302012T1 - Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten - Google Patents

Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten

Info

Publication number: ATE302012T1
Authority: AT; Austria
Prior art keywords: antilplatets; prevention; combined administration; antihypertensive drugs; adp receptor
Prior art date: 1998-06-17

Application number

AT99928498T

Other languages

English (en)

Inventor

Anthony A Coniglio

Francis R Plat

Melvin S Blumenthal

Catherine Cazaubon

Jean-Marc Herbert

Dino Nisato

Original Assignee

Bristol Myers Squibb Co

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-17

Filing date

1999-06-09

Publication date

2005-09-15

1999-06-09 Application filed by Bristol Myers Squibb Co, Sanofi Aventis filed Critical Bristol Myers Squibb Co

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE302012T1 publication Critical patent/ATE302012T1/de

Links

239000002220 antihypertensive agent Substances 0.000 title abstract 2
206010008118 cerebral infarction Diseases 0.000 title abstract 2
229940127088 antihypertensive drug Drugs 0.000 title 1
201000008247 brain infarction Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
239000005541 ACE inhibitor Substances 0.000 abstract 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 abstract 1
102000015427 Angiotensins Human genes 0.000 abstract 1
108010064733 Angiotensins Proteins 0.000 abstract 1
239000005552 B01AC04 - Clopidogrel Substances 0.000 abstract 1
239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
102000007466 Purinergic P2 Receptors Human genes 0.000 abstract 1
108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
229940127218 antiplatelet drug Drugs 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 abstract 1
229960003009 clopidogrel Drugs 0.000 abstract 1
229960002490 fosinopril Drugs 0.000 abstract 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
229960002198 irbesartan Drugs 0.000 abstract 1
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 abstract 1
229950000973 omapatrilat Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AT99928498T 1998-06-17 1999-06-09 Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten ATE302012T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8965098P	1998-06-17	1998-06-17
PCT/US1999/012934 WO1999065500A1 (en)	1998-06-17	1999-06-09	Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination

Publications (1)

Publication Number	Publication Date
ATE302012T1 true ATE302012T1 (de)	2005-09-15

Family

ID=22218835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99928498T ATE302012T1 (de)	1998-06-17	1999-06-09	Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten

Country Status (10)

Country	Link
US (1)	US6248729B1 (de)
EP (1)	EP1087775B1 (de)
JP (2)	JP4588877B2 (de)
AT (1)	ATE302012T1 (de)
AU (1)	AU750122C (de)
CA (1)	CA2332608C (de)
DE (1)	DE69926750T2 (de)
ES (1)	ES2246575T3 (de)
PT (1)	PT1087775E (de)
WO (1)	WO1999065500A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2783422A1 (fr) *	1998-09-21	2000-03-24	Sanofi Sa	Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
RU2245147C2 (ru) *	1999-03-29	2005-01-27	Бристол-Маерс Сквибб Компани	Применение ингибитора вазопептидазы для лечения стенокардии
CA2379666C (en) *	1999-07-21	2009-10-13	Takeda Chemical Industries, Ltd.	Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
SE9904377D0 (sv) *	1999-12-01	1999-12-01	Astra Pharma Prod	Pharmaceutical combinations
JP2002138054A (ja) *	2000-08-25	2002-05-14	Takeda Chem Ind Ltd	フィブリノーゲン低下剤
CA2420055C (en) *	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Fibrinogen-lowering agent
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002217464B2 (en) *	2000-12-25	2004-12-16	Daiichi Sankyo Company, Limited	Medicinal compositions containing aspirin
CA2445860A1 (en)	2001-04-30	2002-11-07	Shire Laboratories Inc.	Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
US6576256B2 (en) *	2001-08-28	2003-06-10	The Brigham And Women's Hospital, Inc.	Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2005508358A (ja) *	2001-10-25	2005-03-31	デポメド・インコーポレイテッド	胃滞留型ロサルタン投与量を用いる治療方法
MXPA04004844A (es) *	2001-11-23	2004-07-30	Solvay Pharm Gmbh	Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.
WO2003070278A1 (en) *	2002-02-19	2003-08-28	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
US20040005358A1 (en) *	2002-04-23	2004-01-08	Slugg Peter H.	Modified-release vasopeptidase inhibitor formulation, combinations and method
US8980870B2 (en) *	2002-09-24	2015-03-17	Boehringer Ingelheim International Gmbh	Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
US20050054731A1 (en) *	2003-09-08	2005-03-10	Franco Folli	Multi-system therapy for diabetes, the metabolic syndrome and obesity
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
EP1812429A4 (de) *	2004-09-29	2010-07-21	Portola Pharm Inc	Substituierte 2h-1,3-benzoxazin-4(3h)-one
ME01615B (me) *	2004-11-05	2014-09-20	Boehringer Ingelheim Int	Dvoslojna tableta koja sadrži telmisartan i amlodipin
US20060201958A1 (en) *	2005-02-27	2006-09-14	Tieben Anthony M	Mask container
US20070015839A1 (en) *	2005-07-14	2007-01-18	Franco Folli	Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20080118572A1 (en) *	2006-10-10	2008-05-22	Harold Richard Hellstrom	Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
JP5681485B2 (ja)	2007-04-27	2015-03-11	サイデックス・ファーマシューティカルズ・インコーポレイテッド	クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
NZ584686A (en) *	2007-11-06	2013-03-28	Novartis Ag	Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
CA2761455C (en)	2009-05-13	2018-06-12	Cydex Pharmaceuticals, Inc.	Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2038178B (en) *	1978-12-29	1983-03-09	Parcor	Antithrombotic therapeutic compsition
US4591592A (en)	1980-07-29	1986-05-27	Syntex (U.S.A.) Inc.	Acid stabilized compositions of thieno-pyridine derived compounds
FR2530247B1 (fr)	1982-07-13	1986-05-16	Sanofi Sa	Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US4558037A (en) *	1984-06-04	1985-12-10	Merck & Co., Inc.	Cardiovascular composition
FR2623810B2 (fr)	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5270317A (en)	1990-03-20	1993-12-14	Elf Sanofi	N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
CA2053340C (en)	1990-10-18	2002-04-02	Timothy P. Burkholder	Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
FR2672801B1 (fr)	1991-02-14	1995-03-03	Sanofi Sa	Utilisation de derives de tetrahydrothienopyridine comme inhibiteurs de l'angiogenese.
CA2078759C (en)	1991-09-27	2003-09-16	Alan M. Warshawsky	Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
AU657793B2 (en)	1991-09-27	1995-03-23	Merrell Pharmaceuticals Inc.	Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
DE69220744T2 (de)	1991-09-27	1997-11-13	Merrell Pharma Inc	2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
CA2087743C (en) *	1992-02-06	1999-04-27	Akio Odawara	Pharmaceutical composition for inhibiting platelet aggregation
AU668707B2 (en)	1992-02-14	1996-05-16	Merrell Pharmaceuticals Inc.	Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE
DK0640086T3 (da)	1992-05-15	1999-12-06	Merrell Pharma Inc	Mercaptoacetylamido-pyridazo[1,2-a][1,2]diazepin-derivateranvendelige som enkephalinase- og ACE-inhibitorer
RU2124503C1 (ru)	1992-05-18	1999-01-10	И.Р.Сквибб энд Санз, Инк.	Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5504080A (en)	1992-10-28	1996-04-02	Bristol-Myers Squibb Co.	Benzo-fused lactams
DE69329701T2 (de)	1992-10-30	2001-05-10	Merrell Pharmaceuticals Inc., Cincinnati	Mercaptoacetylamid substituiertes bizyclisches laktam zur verwendung als enkephalinase und ace-hemmer
NO941915L (no) *	1993-05-25	1994-11-28	Daiichi Seiyaku Co	Madikament for nervebeskyttelse
US5508272A (en)	1993-06-15	1996-04-16	Bristol-Myers Squibb Company	Compounds containing a fused bicycle ring and processes therefor
US5362727A (en)	1993-07-26	1994-11-08	Bristol-Myers Squibb	Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en)	1993-11-18	1996-06-11	Bristol-Myers Squibb Co.	Compounds containing a fused multiple ring lactam
US5576328A (en)	1994-01-31	1996-11-19	Elf Sanofi	Method for the secondary prevention of ischemic events
FR2744918B1 (fr)	1996-02-19	1998-05-07	Sanofi Sa	Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
WO1998011896A1 (en)	1996-09-18	1998-03-26	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardiovascular disease
FR2783422A1 (fr)	1998-09-21	2000-03-24	Sanofi Sa	Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire

1999
- 1999-06-09 AU AU45551/99A patent/AU750122C/en not_active Expired
- 1999-06-09 PT PT99928498T patent/PT1087775E/pt unknown
- 1999-06-09 DE DE69926750T patent/DE69926750T2/de not_active Expired - Lifetime
- 1999-06-09 WO PCT/US1999/012934 patent/WO1999065500A1/en not_active Ceased
- 1999-06-09 AT AT99928498T patent/ATE302012T1/de active
- 1999-06-09 ES ES99928498T patent/ES2246575T3/es not_active Expired - Lifetime
- 1999-06-09 EP EP99928498A patent/EP1087775B1/de not_active Expired - Lifetime
- 1999-06-09 CA CA2332608A patent/CA2332608C/en not_active Expired - Lifetime
- 1999-06-09 US US09/328,812 patent/US6248729B1/en not_active Expired - Lifetime
- 1999-06-09 JP JP2000554379A patent/JP4588877B2/ja not_active Expired - Lifetime
2010
- 2010-04-22 JP JP2010098640A patent/JP2010159300A/ja active Pending

Also Published As

Publication number	Publication date
DE69926750D1 (de)	2005-09-22
EP1087775B1 (de)	2005-08-17
AU750122C (en)	2003-02-27
PT1087775E (pt)	2005-11-30
AU750122B2 (en)	2002-07-11
CA2332608A1 (en)	1999-12-23
AU4555199A (en)	2000-01-05
CA2332608C (en)	2010-03-23
JP2010159300A (ja)	2010-07-22
US6248729B1 (en)	2001-06-19
EP1087775A1 (de)	2001-04-04
JP4588877B2 (ja)	2010-12-01
EP1087775A4 (de)	2003-01-02
ES2246575T3 (es)	2006-02-16
WO1999065500A1 (en)	1999-12-23
DE69926750T2 (de)	2006-06-29
JP2002518335A (ja)	2002-06-25

Legal Events

Date

Code

Title

Description

2006-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1087775

Country of ref document: EP

Publication	Publication Date	Title
ATE302012T1 (de)	2005-09-15	Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
EE200200086A (et)	2003-04-15	Reniin-angiotensiini süsteemi inhibiitori kasutamine, kombineeritud produkt ja meetod kardiovaskulaarsete haigusjuhtude ärahoidmiseks
EP1510221A4 (de)	2009-04-29	Mittel zur prävention und/oder behandlung für personen mit expression oder aktivierung von her2 und/oder egfr
BRPI0412557A (pt)	2006-09-19	forma de dosagem farmacêutica de eventos cardiovasculares
DK0742711T3 (da)	1999-10-11	Tabletter, som er beskyttet mod misbrug
EP1539234A4 (de)	2006-02-15	Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten
EP1708686A4 (de)	2007-12-26	Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
NO20013855L (no)	2001-10-05	Fast tilstandsform av celecoxib med ökt biotilgjengelighet
ES2017195A6 (es)	1991-01-01	Forma de dosificacion que tiene reducidas posiblidades de abuso.
BR0109966A (pt)	2003-08-05	Combinação de compostos orgânicos
BR0307508A (pt)	2004-12-07	Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
PT828728E (pt)	2003-06-30	Di-hidrobenzofuranos de fenilo
ATE230404T1 (de)	2003-01-15	Cyclohexyldihydrobenzofurane
Muriel-Villoria et al.	1995	Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic
BR0311903A (pt)	2005-06-07	Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
EA200501223A1 (ru)	2006-04-28	Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
WO1994028924A1 (en)	1994-12-22	Combination of angiotensin converting enzyme inhibitors and aii antagonists
HN2001000038A (es)	2005-03-23	Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
KR960706341A (ko)	1996-12-09	유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors)
ATE505464T1 (de)	2011-04-15	Feste form von amg 706 und pharmazeutische zusammensetzungen davon
DK694188D0 (da)	1988-12-13	Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel
Van Gijn et al.	2003	Aspirin and stroke prevention
BG108144A (en)	2004-09-30	New use
MX2010004361A (es)	2010-09-10	Metodos para inhibir infeccion viral.
BR0005319A (pt)	2001-07-17	Tratamento combinado para depressão e ansiedade